Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Repare Therapeutics Temettü

Temettü kriter kontrolleri 0/6

Repare Therapeutics şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	1.9%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-US$1.61
Temettü verim tahmini	0%

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data

Aug 30

Will Repare Therapeutics (NASDAQ:RPTX) Spend Its Cash Wisely?

Jul 12

Repare Therapeutics Inc.'s (NASDAQ:RPTX) 34% Dip In Price Shows Sentiment Is Matching Revenues

May 01

Benign Growth For Repare Therapeutics Inc. (NASDAQ:RPTX) Underpins Stock's 30% Plummet

Mar 12

We Think Repare Therapeutics (NASDAQ:RPTX) Needs To Drive Business Growth Carefully

Feb 15

Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Fly 30% But Investors Aren't Buying For Growth

Dec 20

Here's Why We're Not At All Concerned With Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation

Oct 24

New Forecasts: Here's What Analysts Think The Future Holds For Repare Therapeutics Inc. (NASDAQ:RPTX)

Aug 14

Analysts Are Betting On Repare Therapeutics Inc. (NASDAQ:RPTX) With A Big Upgrade This Week

May 14

Analysts Are Upgrading Repare Therapeutics Inc. (NASDAQ:RPTX) After Its Latest Results

May 12

Repare Therapeutics Inc. (NASDAQ:RPTX) Looks Inexpensive But Perhaps Not Attractive Enough

May 08

Growth Investors: Industry Analysts Just Upgraded Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts By 31%

Mar 03

Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth

Oct 27

Repare Therapeutics: Budding Synthetic Lethality Player With 3 Big Pharma Partners

Sep 07

Repare Therapeutics GAAP EPS of -$0.91 misses by $0.06, revenue of $0.67M

Aug 04

Repare Therapeutics: Interesting Gene Editing Company, But Miles To Go

Jun 27

Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth

Jun 24

Repare Therapeutics (NASDAQ:RPTX) Is In A Good Position To Deliver On Growth Plans

Mar 02

We're Not Worried About Repare Therapeutics' (NASDAQ:RPTX) Cash Burn

Oct 14

We Think Repare Therapeutics (NASDAQ:RPTX) Can Easily Afford To Drive Business Growth

Apr 16

Have Repare Therapeutics Inc. (NASDAQ:RPTX) Insiders Been Selling Their Stock?

Mar 12

Are Institutions Heavily Invested In Repare Therapeutics Inc.'s (NASDAQ:RPTX) Shares?

Feb 08

Repare Therapeutics: CRISPR-Enabled Technology Might Unlock New Therapies

Dec 28

Trade Alert: The Executive VP & Head of Business & Corporate Development Of Repare Therapeutics Inc. (NASDAQ:RPTX), Kim Seth, Has Sold Some Shares Recently

Dec 21

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: RPTX şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: RPTX şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Repare Therapeutics Piyasaya Karşı Temettü Getirisi

RPTX temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (RPTX)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.3%
Sektör Ortalaması (Biotechs)	1.9%
Analist tahmini (RPTX) (3 yıla kadar)	0%

Önemli Temettü: RPTX şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, RPTX şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: RPTX şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: RPTX herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Repare Therapeutics Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting

Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 11% to US$13.71

Will Repare Therapeutics (NASDAQ:RPTX) Spend Its Cash Wisely?

Repare Therapeutics Inc. Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI

Repare Therapeutics Inc. Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Repare Therapeutics Inc.'s (NASDAQ:RPTX) 34% Dip In Price Shows Sentiment Is Matching Revenues

Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1B Mythic Trial Evaluating the Synthetic Lethal Combination of Wee1 and Pkmyt1 Inhibition

Repare Therapeutics Inc. Announces Directorate Changes

Repare Therapeutics Inc., Annual General Meeting, Jun 17, 2024

President exercised options to buy US$125k worth of stock.

Benign Growth For Repare Therapeutics Inc. (NASDAQ:RPTX) Underpins Stock's 30% Plummet

Consensus revenue estimates increase by 33%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664

We Think Repare Therapeutics (NASDAQ:RPTX) Needs To Drive Business Growth Carefully

Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Fly 30% But Investors Aren't Buying For Growth

Executive VP & Chief Medical Officer exercised options to buy US$287k worth of stock.

Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: Rp-1664, an Oral Plk4 Inhibitor, and Rp-3467, an Oral Pol Inhibitor

New major risk - Share price stability

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Here's Why We're Not At All Concerned With Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation

Price target decreased by 14% to US$23.50

Repare Therapeutics Inc. Reports Positive Initial Data from Modules 1 and 2 of its Ongoing Phase 1 Mythic Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib, an ATR Inhibitor

Consensus revenue estimates increase by 32%

Consensus revenue estimates increase by 42%

New Forecasts: Here's What Analysts Think The Future Holds For Repare Therapeutics Inc. (NASDAQ:RPTX)

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Executive VP & Chief Scientific Officer notifies of intention to sell stock

Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials

Consensus revenue estimates increase by 23%, EPS downgraded

Analysts Are Betting On Repare Therapeutics Inc. (NASDAQ:RPTX) With A Big Upgrade This Week

Analysts Are Upgrading Repare Therapeutics Inc. (NASDAQ:RPTX) After Its Latest Results

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Repare Therapeutics Inc. (NASDAQ:RPTX) Looks Inexpensive But Perhaps Not Attractive Enough

Consensus revenue estimates increase by 31%

Growth Investors: Industry Analysts Just Upgraded Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts By 31%

Full year 2022 earnings released: US$0.69 loss per share (vs US$2.83 loss in FY 2021)

Executive VP & Chief Medical Officer exercised options to buy US$725k worth of stock.

Price target decreased to US$26.00

President notifies of intention to sell stock

Consensus revenue estimates increase by 116%

Price target decreased to US$28.88

Consensus revenue estimates increase by 119%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth

Repare Therapeutics: Budding Synthetic Lethality Player With 3 Big Pharma Partners

Consensus revenue estimates increase by 91%

Second quarter 2022 earnings released: US$0.91 loss per share (vs US$0.71 loss in 2Q 2021)

Repare Therapeutics GAAP EPS of -$0.91 misses by $0.06, revenue of $0.67M

Repare Therapeutics: Interesting Gene Editing Company, But Miles To Go

Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth

Price target decreased to US$32.75

Consensus revenue estimates increase by 337%

Consensus forecasts updated

Price target decreased to US$38.11

Price target decreased to US$38.22

Repare Therapeutics Inc. Announces Publication of Preclinical Data in Nature Demonstrating the Potential of PKMYT1 Inhibitor RP-6306 in Tumors With CCNE1 Amplification

Price target decreased to US$38.22

Repare Therapeutics Inc. Presents Updated Clinical Data from the Ongoing Phase 1/2 TRESR Study of RP-3500 Monotherapy in Solid Tumors at the 2022 AACR Annual Meeting

Repare Therapeutics Inc. to Present New Clinical and Preclinical Data at the 2022 AACR Annual Meeting

Consensus forecasts updated

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$43.13

Repare Therapeutics (NASDAQ:RPTX) Is In A Good Position To Deliver On Growth Plans

Repare Therapeutics Inc., Annual General Meeting, May 13, 2022

Repare Therapeutics Inc. Doses First Patient in Phase 1 Clinical Trial of RP-6306 in Combination with Gemcitabine for the Treatment of Advanced Solid Tumors

Executive VP & Chief Scientific Officer exercised options to buy US$976k worth of stock.

Chairman recently bought US$211k worth of stock

High number of new directors

We're Not Worried About Repare Therapeutics' (NASDAQ:RPTX) Cash Burn

Executive Vice President of Discovery recently sold US$228k worth of stock